Results 21 to 30 of about 144,226 (276)

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma

Journal of Hematology & Oncology, 2022
Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies.
Vivian Changying Jiang, Yang Liu, Alexa Jordan, Angela Leeming, Joseph McIntosh, Shengjian Huang, Rongjia Zhang, Qingsong Cai, Zhihong Chen, Yijing Li, Yuxuan Che, Lei Nie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige, Björn Frendéus, Michael Wang   +17 more
doaj   +1 more source

Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy

American Journal of Ophthalmology Case Reports, 2016
Purpose: To describe the effect of rituximab on full-field electroretinography (ERG) in a patient with nonparaneoplastic autoimmune retinopathy (npAIR). Observations: A 58-year-old male patient with visual complaints, positive anti-retinal antibodies and
Gunay Uludag, Sumru Onal, Serra Arf, Isil Sayman Muslubas, Fatih Selcukbiricik, Aylin Koc Akbay, Nil Molinas Mandel   +6 more
doaj   +1 more source

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Haematologica, 2013
Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high ...
Clifton C. Mo, Ndegwa Njuguna, Paul V. Beum, Margaret A. Lindorfer, Berengere Vire, Elinor Lee, Gerald Marti, Wyndham H Wilson, Ronald P. Taylor, Adrian Wiestner   +9 more
doaj   +1 more source

Rituximab in dermatology

Actas Dermo-Sifiliográficas (English Edition), 2013
Rituximab was introduced into clinical practice as a medication with considerable potential. Its use in patients with B-cell lymphoma and rheumatoid arthritis revealed numerous indications in autoimmune diseases, many of which involve the skin, thus requiring dermatologists to become familiar with both the characteristics of anti-CD20 antibodies and ...
A, España, E, Ornilla, C, Panizo
openaire   +2 more sources

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

Journal of Hematology & Oncology, 2012
Background The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab.
Zinzani Pier, Khuageva Nuriet K, Wang Huaqing, Garicochea Bernardo, Walewski Jan, Van Hoof Achiel, Soubeyran Pierre, Caballero Dolores, Buckstein Rena, Esseltine Dixie-Lee, Theocharous Panteli, Enny Christopher, Zhu Eugene, Elsayed Yusri A, Coiffier Bertrand   +14 more
doaj   +1 more source

Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study

BMC Rheumatology, 2022
Background This pilot study’s primary aim was to determine if oligoclonal B cell expansion in children with Juvenile Dermatomyositis (JDM) predicts response to Rituximab therapy.
Elisa Ochfeld, Victoria Hans, Wil Marin, Najah Ahsan, Gabrielle Morgan, Lauren M. Pachman, Amer Khojah   +6 more
doaj   +1 more source

Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing [PDF]

The Korean Journal of Internal Medicine, 2023
Background/Aims Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge.
Min Ji Jeon, Eun Sang Yu, Chul Won Choi, Dae Sik Kim   +3 more
doaj   +1 more source

Update on rituximab [PDF]

Annals of the Rheumatic Diseases, 2005
Rituximab is a chimeric monoclonal antibody that was developed for the treatment of B cell lymphomas.1 It is directed against the CD20 cell surface molecule.2 CD20 is a tetraspan membrane protein that is present only on B cells, and is expressed initially at the immature B cell stage, remaining until the final differentiation into plasma cells.
openaire   +2 more sources

Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

Journal of Immunology Research, 2014
We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy.
Heiner Zimmermann, Theresa Weiland, Jamie P. Nourse, Maher K. Gandhi, Petra Reinke, Ruth Neuhaus, Mohsen Karbasiyan, Barbara Gärtner, Ioannis Anagnostopoulos, Hanno Riess, Ralf U. Trappe, Stephan Oertel   +11 more
doaj   +1 more source

Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. [PDF]

PLoS ONE, 2013
The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders. Intravenous administration of rituximab is associated with infusion times of 4-6 hours, and can
Cheng-Ping Mao, Martin R Brovarney, Karim Dabbagh, Herbert F Birnböck, Wolfgang F Richter, Christopher J Del Nagro   +5 more
doaj   +1 more source